Royal Bank Of Canada Initiates Coverage on Athenex, Inc. (ATNX)
Analysts at Royal Bank Of Canada assumed coverage on shares of Athenex, Inc. (NASDAQ:ATNX) in a research note issued to investors on Thursday, The Fly reports. The firm set an “outperform” rating on the stock.
Separately, Deutsche Bank AG began coverage on Athenex in a research report on Monday, July 10th. They issued a “buy” rating and a $20.00 price target for the company.
Shares of Athenex (NASDAQ ATNX) traded down 0.18% during trading on Thursday, hitting $16.41. The company had a trading volume of 187,513 shares. The stock’s 50-day moving average price is $16.29 and its 200 day moving average price is $16.48. The company’s market capitalization is $936.40 million. Athenex has a 52 week low of $11.21 and a 52 week high of $20.79.
Athenex (NASDAQ:ATNX) last issued its quarterly earnings results on Monday, August 14th. The company reported ($0.88) earnings per share (EPS) for the quarter. The company had revenue of $4.60 million during the quarter.
COPYRIGHT VIOLATION WARNING: “Royal Bank Of Canada Initiates Coverage on Athenex, Inc. (ATNX)” was posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/14/royal-bank-of-canada-initiates-coverage-on-athenex-inc-atnx.html.
In related news, CEO Johnson Yiu Nam Lau acquired 25,200 shares of the firm’s stock in a transaction dated Monday, June 19th. The stock was acquired at an average price of $11.00 per share, with a total value of $277,200.00. Following the acquisition, the chief executive officer now directly owns 2,722,722 shares in the company, valued at approximately $29,949,942. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Song-Yi Zhang acquired 328,637 shares of the firm’s stock in a transaction dated Monday, June 19th. The stock was bought at an average cost of $11.00 per share, with a total value of $3,615,007.00. Following the acquisition, the director now owns 4,000 shares in the company, valued at $44,000. The disclosure for this purchase can be found here.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp acquired a new position in Athenex in the 2nd quarter worth about $240,000. Tudor Investment Corp ET AL acquired a new position in shares of Athenex during the second quarter valued at approximately $320,000. Goldman Sachs Group Inc. acquired a new position in shares of Athenex during the second quarter valued at approximately $601,000. California Public Employees Retirement System acquired a new position in shares of Athenex during the second quarter valued at approximately $800,000. Finally, Vanguard Group Inc. acquired a new position in shares of Athenex during the second quarter valued at approximately $800,000. 0.88% of the stock is owned by institutional investors.
Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.
Receive News & Ratings for Athenex Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex Inc. and related companies with MarketBeat.com's FREE daily email newsletter.